Across TCGA pan-cancer cohorts, ANXA10 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of ANXA10’s most consistent transcriptional readouts.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ANXA10 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ANXA10 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.
PDAC and LUAD are the cancer types where ANXA10 tumor–normal differential expression is most reproducible.